152 related articles for article (PubMed ID: 15678151)
1. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.
Sang H; Pisarev VM; Chavez J; Robinson S; Guo Y; Hatcher L; Munger C; Talmadge CB; Solheim JC; Singh RK; Talmadge JE
Cancer Gene Ther; 2005 Apr; 12(4):427-37. PubMed ID: 15678151
[TBL] [Abstract][Full Text] [Related]
2. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.
Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE
Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
5. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
Solheim JC; Reber AJ; Ashour AE; Robinson S; Futakuchi M; Kurz SG; Hood K; Fields RR; Shafer LR; Cornell D; Sutjipto S; Zurawski S; LaFace DM; Singh RK; Talmadge JE
Cancer Gene Ther; 2007 Apr; 14(4):364-71. PubMed ID: 17235356
[TBL] [Abstract][Full Text] [Related]
6. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
8. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
10. Cancer gene therapy using in vivo electroporation of Flt3-ligand.
Shimao K; Takayama T; Enomoto K; Saito T; Nagai S; Miyazaki J; Ogawa K; Tahara H
Int J Oncol; 2005 Aug; 27(2):457-63. PubMed ID: 16010428
[TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
12. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.
Lewis JD; Shearer MH; Kennedy RC; Bright RK
Cancer Res; 2005 Apr; 65(7):2938-46. PubMed ID: 15805297
[TBL] [Abstract][Full Text] [Related]
13. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
14. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.
Met O; Balslev E; Flyger H; Svane IM
Breast Cancer Res Treat; 2011 Jan; 125(2):395-406. PubMed ID: 20336365
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene.
Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q
Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.
Matsumura N; Mandai M; Hamanishi J; Yamaguchi K; Fukuhara K; Yagi H; Higuchi T; Takakura K; Fujii S
Oncol Rep; 2008 Feb; 19(2):505-15. PubMed ID: 18202801
[TBL] [Abstract][Full Text] [Related]
17. Immunization with truncated sequence of Telomerase Reverse Transcriptase induces a specific antitumor response in vivo.
Qiu J; Li GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W
Acta Oncol; 2007; 46(7):961-8. PubMed ID: 17917827
[TBL] [Abstract][Full Text] [Related]
18. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.
Edukulla R; Woller N; Mundt B; Knocke S; Gürlevik E; Saborowski M; Malek N; Manns MP; Wirth T; Kühnel F; Kubicka S
Cancer Res; 2009 Feb; 69(4):1448-58. PubMed ID: 19190348
[TBL] [Abstract][Full Text] [Related]
19. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
